Effect of Namenda on Short Term Memory and Attention in Patients With Mild to Moderate Traumatic Brain Injury

University of Missouri (MU)

Status and phase

Terminated

Phase 4

Conditions

Traumatic Brain Injury

Treatments

Drug: Memantine

Drug: Placebo

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT00462228

NAM-MD-44

Details and patient eligibility

About

The purpose of this study is to determine whether memantine (Namenda) improves memory and attention in patients with mild to moderate traumatic brain injury.

Full description

Background and significance:

Each year in the United States approximately 1.5 million people sustain a traumatic brain injury (TBI) and of these approximately 80-90,000 result in long-term or lifelong disability. An estimated 5.3 million people are currently living with a disability due to TBI. The Centers for Disease Control (CDC) estimated that about 75% (1.1 million) of the reported TBIs are concussions or other forms of mild TBIs (MTBI). However, the incidence of MTBI has been vastly underestimated according to a CDC Report to Congress.

The long term problem associated with MTBI is primarily memory impairment. Memory impairment resulting form MTBI is not likely to improve with time beyond the initial stabilizing period of about one year post-injury. Dementia from Alzheimer's Disease produces cognitive problems that are similar to those experienced by patients with mild to moderate traumatic brain injury. The efficacy of Namenda for treatment of cognitive problems due to Alzheimer's Dementia suggests it may have efficacy for treatment of short term memory and attention deficits in patients with mild to moderate traumatic brain injury.

Overall Design and Plan of Study:

Twenty post-TBI patients whose TBI occurred at least 1 year prior to beginning the study will be recruited for this pilot study. Patients who meet screening criteria will have cognitive abilities assessed at baseline and at subsequent visits while taking Namenda or placebo. Patients will be randomly assigned to begin either Namenda or placebo and will then crossover to the alternate treatment. Each patient will participate in the study for a total of 32 to 34 weeks. Patients completing the study will have 10 total visits and 6 visits at which a cognitive test battery will be administered. This will include 24 weeks of study drug treatment (12 weeks of Namenda and 12 weeks of placebo) and two 4-week washout periods. Patients will be titrated up to 20 mg of Namenda per day. Namenda and placebo will be provided by Forest Laboratories Inc.

Cognitive screening criteria include a Galveston Orientation and Amnesia Test (GOAT) score of at least 75, and either a Mini-Mental State Exam (MMSE) score of 20 to 27 obtained at the screening visit, or a California Verbal Learning Test (CVLT) total score for trials 1-5 one standard deviation lower than the age matched normative score. The CVLT score for inclusion may be obtained from the medical record provided that the CVLT testing occurred one year or more post TBI and within two years of study entry.

The cognitive test battery measurements will be made at the first baseline before Namenda or placebo administration (week 0), and at weeks 6, & 12 after Namenda or placebo administration. After washout for 4 weeks, the second baseline (week 16) will be assessed, and the cognitive test battery will be administered again at weeks 22 & 28 after Namenda or placebo administration.

The cognitive test battery used to assess efficacy will utilize the following tests;

Verbal Memory: Hopkins Verbal Learning Test Revised (HVLT-R). Visual Memory: Brief VisuoSpatial Memory Test Revised (BVMT-R). Speed of processing: Trail Making Test Part A. Attention: Trail Making Test Part B. Memory/processing speed: Symbol Digit Modality Test (SDMT).

The primary endpoints for cognitive assessment will be the HVLT-R and the BVMT-R. The 6 different forms of the HVLT-R and BVMT-R will be administered at each of the 6 cognitive test battery assessments. The sequence of forms administered will be randomized. The other listed cognitive tests will be considered secondary endpoints. An additional secondary efficacy endpoint will be the Physicians Global Impression of Change which will be recorded with the same visit frequency as other cognitive tests.

In addition to the neuropsychological tests, patients will have physical examinations, electrocardiograms, and laboratory tests of blood and urine. Safety and tolerability will be monitored by clinical assessment, reporting of adverse events, and laboratory values. Patient health will be assessed at clinic visits every 3-6 weeks throughout the study. Serum pregnancy (for females of child bearing potential) will be completed at screening and at weeks 12 and 28. Urine pregnancy tests will be completed at baseline (week 0) and weeks 16 & 32. A Safety Officer will be utilized as the primary means of monitoring safety of the study. The Safety Officer will be a physician not associated with the study in any other capacity. The Safety Officer will be given periodic reports of clinical assessments, laboratory values, and adverse events.

Enrollment

11 patients

Sex

All

Ages

18 to 50 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients will have persistent memory and attention deficits due to a closed traumatic brain injury not less than one year prior to entrance in the study.
Meet or exceed American Congress of Rehabilitation Medicine (ACRM) criteria for mild TBI.
Mini-Mental State Exam (MMSE) score of 20 to 27 at the screening visit or a California Verbal Learning Test (CVLT) score for trials 1-5 one standard deviation lower than the age matched normative score. The CVLT score from the medical record may be used for entry criteria if it was obtained one year or more post-TBI and within two years of study entry.
Galveston Orientation and Amnesia Test (GOAT) score of at least 75.
Be of sufficient cognitive ability to complete neuropsychological tests.
Male or female, 18-50 years of age.
Females of childbearing potential must use acceptable means of birth control and have a negative screening beta-human chorionic gonadotrophin (b-HCG) pregnancy test. Acceptable birth control includes hormonal birth control (such as oral birth control pills, implanted or injected contraceptives), an intrauterine device (IUD), surgical sterilization (such as tubal ligation or hysterectomy), a spermicide with barrier methods (condoms or diaphragm), or a partner who has had a vasectomy.
Patients taking donepezil (Aricept) or rivastigmine (Exelon) must be at a steady state dose for a minimum of six months.
Patients taking any other medication(s) affecting cognition must be at a steady state dose for a minimum of two months.
Able to provide written informed consent.
Able to read, write, and speak in English.
Willing and able to comply with the physician's instructions for all aspects of the study.

Exclusion criteria

Patients must not have any medical or psychiatric disorder that in the opinion of the PI would interfere with or bias the assessment of efficacy or place their health at risk when placed on the memantine (Namenda) regimen.
Patients with a history of seizure are excluded.
Patients with a history of severe renal insufficiency are excluded.
Patients must not have taken any experimental drug within the last 30 days prior to entering the protocol.
Patients must not have taken any drug known to have major organ system toxicity within the last 30 days prior to entering the protocol.
Women who are pregnant, nursing, or intend to become pregnant during the study are excluded.
Patients with a penetrating TBI are excluded.
Patients whose screening laboratory values are 1.5 times greater than upper limits of normal range(ULN) are excluded.
Patients with systolic blood pressure greater than 180 mm Hg or less than 90 mm Hg or diastolic blood pressure greater than 105 mm Hg or less than 50 mm Hg at the screening visit are excluded.
Concomitant use of amantadine (Symmetrel) is prohibited and a washout period of 4 weeks is required before study entry.